Skip to main navigation Skip to search Skip to main content

A three-year, multi-center, double-blind extension study to evaluate the long-term safety and efficacy of ligelizumab in patients who completed ligelizumab's Phase III studies in food allergy

Project: Research

Project Details

StatusActive
Effective start/end date07/15/23 → 12/31/26

Funding

  • Novartis Pharmaceuticals Corporation: $93,143.32